Who’s Afraid Of Payment Reform? CMS Cardiac Bundle Shows How Changes Can Be Positive For Rx
Executive Summary
Medicare’s proposed demonstration project to change payments in Medicare Part B aside, when it comes to ideas for payment and delivery reform, prescription drugs should do pretty well. CMS’ new proposal to bundle cardiac payments is a timely case in point.
You may also be interested in...
Part B Demo Comments Overwhelmingly Negative, Uniform In Content
More than 90% of comments submitted on proposed Medicare payment experiment for Part B drugs were negative, and most were submitted by patients and health care providers.
Ending “Buy-And-Bill” in Oncology: The Question is How, Not If
The public policy debate over affordability of cancer care is approaching consensus on the need to end the “buy-and-bill” model for chemotherapy. How, and how fast, are the key remaining questions. For biopharma manufacturers, there are good reasons to embrace the change.
Inter-Agency User Fees? US FDA/ARPA-H Relationship Could Get Interesting
The Biden Administration’s signature health research agency ARPA-H is still in the formative stages. Authorizing legislation moving through Congress could set up a very interesting dynamic when it comes to working with the US FDA.